Our R&D partners

VIB has many research partners both in and outside Belgium. We are proud to collaborate with, among many others: 


Oxford Biomedica

Oxford BioMedica and VIB collaborate on the the further preclinical evaluation of MoNuDin® for the treatment of amyotrophic lateral sclerosis (ALS).

Sanofi Aventis

Acambis (now Sanofi Aventis) and VIB are developing a universal flu vaccine for humans. The universal influenza vaccine has been pioneered by researchers from VIB and Ghent University.


​Cellectis, the French genome engineering specialist, and VIB together conduct research into new approaches to cure haemophilia.

BASF Plant Science

BASF Plant Science and VIB collaborate on plant genetic mechanisms that increase yield and improve tolerance to environmental stress such as drought and cold.​



Ablynx is engaged in the discovery and development of Nanobodies® to treat a range of serious human diseases. It was established as a spin-off of VIB and the Vrije Universiteit Brussel (VUB).​

Bayer CropScience

VIB and Bayer CropScience have an ongoing collaboration into the mechanisms with which plants cope with stress factors such as extreme temperatures or persistent drought. The results are crucial for the development of crops with higher yield.​

Read more about how to become an R&D partner of VIB.



 Green biotech cluster - Plant sciences in Ghent, Flanders, Belgium